4.5 Article

Using gene delivery to protect HIV-susceptible CNS cells: Inhibiting HIV replication in microglia

Journal

VIRUS RESEARCH
Volume 118, Issue 1-2, Pages 87-97

Publisher

ELSEVIER
DOI: 10.1016/j.virusres.2005.11.016

Keywords

HIV; NeuroAIDS; microglia; gene therapy; SV40 vectors; alpha 1-antitrypsin

Categories

Funding

  1. NIAID NIH HHS [AI48244] Funding Source: Medline
  2. NIMH NIH HHS [MH69122, MH70287] Funding Source: Medline

Ask authors/readers for more resources

Antiretroviral chemotherapy penetrates the CNS poorly. CNS HIV, thus sheltered, may injure the brain and complicate control of systemic HIV infection. Microglial cells play a major role in HIV persistence in the CNS but are rarely targeted for gene delivery. Because recombinant SV40 vectors (rSV40s) transduce other phagocytic cells efficiently, we tested rSV40 delivery of anti-HIV genetic therapy to microglial cells. Microglia prepared as enriched cultures from human fetal brain, were transduced with marker vectors, SV(RFP) and SV(Nef/FLAG), respectively, carrying DsRed and HIV-1 Nef bearing a FLAG epitope. By immunostaining and FACS, 95% of unselected cells expressed the transgenes, without detectable toxicity. Microglia were transduced with SV(AT), carrying human alpha 1-antitrypsin (alpha 1AT), which blocks Env and Gag processing. SV(AT)-treated microglia strongly resisted challenge with HIV-1BaL, even when microglia were transduced with SV(AT) following HIV challenge. Thus, rSV40s effectively transduce microglia and protect them from HIV. (c) 2005 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available